Health Condition 1: L100- Pemphigus vulgaris
Conditions
Interventions
Intervention1: Azathioprine and predisolone: Azathioprine will be started at 50mg/day if there is no significant clinical, biochemicaland hematological side effects are seen , dose as per TPMT will be
Sponsors
PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: Patient who has recently received 2 dose of rituximab 1gm, 2 weeks apart for moderate to severe pemphigus vulgaris or recalcitrant pemphigus vulgaris, Age more than 18 years, Willing for regular follow up for 60 weeks at proposed intervals.
Exclusion criteria
Exclusion criteria: Individual upto 18 years of age, Inability to follow up till 60 weeks,Pregnant or lactating female,Elderly patient aged 80 years or older for practical difficulty in following up or unreliable patient,Significant anemia, leukopenia and thrombocytopenia,Reduced thiopurine methyl transferase activity, Pre-existing liver disease/ chronic viral hepatitis/ transaminitis,Chronic infection or immunosuppressed state, History sugesstive of allergy to rituximab /azathioprine,Females planning to start family in next 60 weeks or not willing for contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to relapseTimepoint: 15 months | — |
Secondary
| Measure | Time frame |
|---|---|
| proportion of patients achieving remission, time to clinical remission, duration of remission, side effects of treatment.Timepoint: 15 months | — |
Countries
India
Contacts
Public ContactNeha Thakur
PGIMER
Outcome results
None listed